Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: A new therapeutic approach to immune-mediated inflammatory diseases;Indications et modalités d'utilisation des antagonistes de l'interleukine (IL)-1 dans les dermatoses inflammatoires

Annales de Dermatologie et de Venereologie

Volumn 139, Issue 6-7, 2012, Pages 459-467

  Lipsker, D ^a   Lenormand, C ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Anakinra; Anti IL 1; Auto inflammatory diseases; Cryopyrinopathies; Neutrophilic dermatoses; NLRP3

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT ONSET STILL DISEASE; ARTICLE; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; DRUG EFFICACY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; HUMAN; INFLAMMATORY DERMATOSIS; JUVENILE RHEUMATOID ARTHRITIS; MEDLINE; MUCKLE WELLS SYNDROME; PANNICULITIS; PUSTULAR PSORIASIS; PYODERMA GANGRENOSUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHNITZLER SYNDROME; SKIN DISEASE; SUPPURATIVE HIDRADENITIS;

EID: 84862901218     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2012.03.012     Document Type: Short Survey

References (38)

1. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32.
2. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011;41:1203-17.
3. Going JJ. Is the pathogenesis of Sweet's syndrome mediated by interleukin-1? Br J Dermatol 1987;116:282-3.
4. Bourke JF, Jones JL, Fletcher A, Graham-Brown RA. An immunohistochemical study of the dermal infiltrate and epidermal staining for interleukin 1 in 12 cases of Sweet's syndrome. Br J Dermatol 1996;134:705-9. (Pubitemid 26120739)
5. Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998;39:940-3. (Pubitemid 28547725)
6. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-8.
7. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621-68.
8. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
9. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
10. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin- 1 receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4. (Pubitemid 36706554)
11. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammaytory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009;360:2426-37.
12. Reddy S, Jia S, Geoffrey R, Suchi M, Broeckel U, Hessner MJ, et al. An autoinflammatory disease due to homozygous deletion of the ILR1N locus. N Engl J Med 2009;360:2438-44.
13. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365:620-8.
14. Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011;89:432-7.
15. Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009;88:23-31.
16. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 2001;80:37-44. (Pubitemid 32066377)
17. de Koning HD, Bodar EJ, van der Meer JW, Simon A, Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137-48. (Pubitemid 350151505)
18. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010;5:38.
19. Martinez-Taboada VM, Fontalba A, Blanco R, Fernández-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum 2005;52:2226-7. (Pubitemid 40994347)
20. Kluger N, Rivière S, Guillot B, Bessis D. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome. Acta Derm Venereol 2008;88:287-8. (Pubitemid 351743881)
21. Wastiaux H, Barbarot S, Gagey-Caron V, Berthelot JM, Hamidou M, Stalder JF. Schnitzler syndrome: a dramatic improvement with anakinra. J Eur Acad Dermatol Venereol 2009;23:85-7.
22. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848-50 [epub ahead of print].
23. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
24. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
25. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther 2011;13:R91.
26. Delluc A, Limal N, Puéchal X, Francès C, Piette JC, Cacoub P. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 2008;67:278-9.
27. Kluger N, Gil-Bistes D, Guillot B, Bessis D. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret) in a case of refractory Sweet syndrome. Dermatology 2011;222: 123-7.
28. Lipsker D, Perrigouard C, Foubert A, Cribier B. Anakinra for difficult-to-treat neutrophilic panniculitis. IL-1 blocade as a promising treatment option in neutrophil-mediated inflammatory skin disease. Dermatology 2010;220:264-7.
29. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010;153:66-7.
30. Colina M, Pizzirani C, Khodeir M, Falzoni S, Bruschi M, Trotta F, et al. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) 2010;49:1416-8.
31. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008;149:284-6.
32. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 2006;45:491-2.
33. Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 2008;75:622-4.
34. Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol 2012;148:297-9.
35. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409-15.
36. Lin Z, Hegarty JP, Lin T, Ostrov B, Wang Y, Yu W, et al. Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. Inflamm Bowel Dis 2011;17:E41-2.
37. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010;146:1265-70.
38. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011:CD008794.